Day One Biopharmaceuticals, Inc. (DAWN)

NASDAQ: DAWN · IEX Real-Time Price · USD
13.25
-0.60 (-4.33%)
Jan 27, 2022 4:00 PM EST - Market closed
Market Cap820.56M
Revenue (ttm)n/a
Net Income (ttm)-186.88M
Shares Out61.93M
EPS (ttm)-8.85
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume129,203
Open14.03
Previous Close13.85
Day's Range12.99 - 14.30
52-Week Range12.99 - 28.70
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About DAWN

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceutic...

IndustryBiotechnology
IPO DateMay 27, 2021
Employees42
Stock ExchangeNASDAQ
Ticker SymbolDAWN
Full Company Profile

Financial Performance

Financial Statements

News

Day One Announces First Patient Dosed in Phase 2 Monotherapy Study in RAF-altered Solid Tumors

SOUTH SAN FRANCISCO, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted ...

2 months ago - GlobeNewsWire

Day One Reports Third Quarter 2021 Financial Results and Corporate Progress

Enrollment Progresses in the Pivotal Phase 2 FIREFLY-1 Clinical Trial of DAY101 in Patients with pLGG; Initial Data Expected in 1H 2022

2 months ago - GlobeNewsWire

Day One Appoints Jaa Roberson as Chief People Officer

SOUTH SAN FRANCISCO, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted...

4 months ago - GlobeNewsWire

Day One Appoints Scott Garland to Board of Directors

SOUTH SAN FRANCISCO, Calif., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted ...

5 months ago - GlobeNewsWire

Day One Reports Second Quarter 2021 Financial Results and Corporate Progress

DAY101 Granted Rare Pediatric Disease Designation from FDA

5 months ago - GlobeNewsWire

Day One Biopharma's experimental glioma drug gets an orphan designation in Europe

Shares of Day One Biopharmaceuticals Inc. gained 9.4% in premarket trading on Monday after the company said its experimental glioma treatment received an orphan designation in Europe. The drug candidate...

7 months ago - Market Watch

Day One Receives Orphan Designation from the European Commission for DAY101 for the Treatment of Glioma

SOUTH SAN FRANCISCO, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for p...

7 months ago - GlobeNewsWire

Day One Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchas...

SOUTH SAN FRANCISCO, Calif., June 01, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing tar...

7 months ago - GlobeNewsWire

Day One Announces Pricing of Upsized Initial Public Offering

SOUTH SAN FRANCISCO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targ...

8 months ago - GlobeNewsWire

Day One Biopharmaceuticals upsizes IPO to 10 million shares from 8.4 million

Day One Biopharmaceuticals Inc. , which specializes in developing cancer treatments for children, upsized its initial public offering on Wednesday to 10 million shares from a previous plan to offer 8.4 ...

8 months ago - Market Watch